Company Encyclopedia
View More
name
TransCode Therapeutics
RNAZ.US
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc.
1.907 T
RNAZ.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer

    TransCode Therapeutics Inc. has appointed Dr. Michel Janicot as Senior Development Officer. With over 35 years of experience in pharmaceutical research and oncology drug development, Dr. Janicot will support the company's lead oncology programs, TTX-MC138 and Seviprotimut-L, as they move toward late-stage clinical trials.

    Reuters·
    US
    RNAZ
    +0.93%
    Reuters·
    US
    RNAZ
    +0.93%

    TransCode Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RNAZ
    +0.93%
    LB filings·
    US
    RNAZ
    +0.93%

    TransCode Therapeutics Amends Preferred Stock Designation

    TransCode Therapeutics (RNAZ) amended its Certificate of Designation for Series A and B Preferred Stock on October 27, 2025, clarifying stock issuance limitations and removing conversion rights upon Nasdaq delisting. Analysts rate RNAZ as a Buy with a $280.00 target, but Spark's AI Analyst suggests it is an Underperform due to high financial risks, lack of revenue, and negative equity. The company, focused on cancer treatment, has a market cap of $11.16M and faces continued downward pressure on its stock.

    Tip Ranks·
    US
    RNAZ
    +0.93%
    Tip Ranks·
    US
    RNAZ
    +0.93%

    TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent

    TransCode Therapeutics Inc. has filed Amendment No. 2 to its Current Report on Form 8-K, reporting the effective date of its Contingent Value Rights (CVR) Agreement and a change in the rights agent. The CVR Agreement with Vstock Transfer, LLC is included as an exhibit in the filing.

    Reuters·
    US
    RNAZ
    +0.93%
    Reuters·
    US
    RNAZ
    +0.93%

    TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease

    TransCode Therapeutics Inc. has completed its Phase 1a trial for TTX-MC138, an inhibitor of microRNA-10b, in metastatic disease. The trial met safety endpoints and established a recommended Phase 2 dose, with no significant safety events. Preliminary data showed stable disease in 44% of patients. The company plans to advance to Phase 2a trials to further assess efficacy in selected metastatic diseases.

    Reuters·
    US
    RNAZ
    +0.93%
    Reuters·
    US
    RNAZ
    +0.93%